Not all cancer patients need chemotherapy. ATaraxis AI collected $ 20 million to fix this.
Artificial intelligence is a great direction in caring for cancer, and it often focuses on detecting cancer as soon as possible. This is very logical, given that cancer is less deadly, it has been discovered early.
But the least basic question arises: If someone has cancer, is aggressive treatment such as chemotherapy? This is the problem that Ataraxis AI is trying to solve.
The New York -based start -up company focuses its headquarters on the use of artificial intelligence to predict accurately not only if the patient has cancer, but also the problem of cancer within 5 to 10 years. If there is no little chance to return to cancer, chemotherapy can be completely avoided – which saves a lot of money, while avoiding the reputable side effects of treatment.
Ataraxis AI is now planning to launch his first commercial test for breast cancer, for American oncologists in the coming months, says its co -founder Jan Witowski Techcrunch. To support the launch and expansion of other types of cancer, the startup company raised the A series of $ 20.4 million, and Teccrunch is told exclusively.
The tour led AIX Ventures with the participation of Thiel Bio, Founders Fund, Floating Point, BERTELSMANN and current investors in giant projects and clear projects. Ataraxis back From the ghost last year with the seed tour of $ 4 million.
Ataraxis participated in the establishment of Witowski and KrZysztof Geras, Assistant Professor at the New York University Faculty of Medicine, which focuses on artificial intelligence.
Ataraxis technology is supported by the artificial intelligence model that extracts information from high -resolution images of cancer cells. Wittski said the model was trained in hundreds of millions of real photos of thousands of patients. A recent study showed that Ataraxis technology was 30 % more accurate than the current breast cancer level, at Ataraxis.
In the long run, Ataraxis has great ambitions. It wants to affect its tests on at least half of the new cancer cases by 2030. It also looks at itself as the company Frontier AI, which builds its own models, promotes The head of Amnesty International in Mita Yan Lacon As an Amnesty International Adviser.
“I think at Ataraxis that we are trying to build what is basically the Frontier AI laboratory, but for healthcare applications,” Witowski said. “Because many of these problems require a very new technology.”
The artificial intelligence boom led to a rush of donations for emerging companies in cancer care. Valler Laboratory She raised 22 million dollars To help patients discover their treatment plan in May 2024, for example. There is also a group of detection companies on behalf of cancer, such as Manas Ai She raised $ 24.6 million in January 2025 Red Hoffman, co -founder of LinkedIn.
